To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Summary
HR9661, introduced by Rep. Langworthy and cosponsored by Rep. Schrier, would codify that the FDA's default expectation for biosimilar licensure does not include clinical pharmacodynamics or comparative efficacy studies. This regulatory change reduces development costs for biosimilar manufacturers, benefiting companies like $VTRS and $TEVA that have active biosimilar pipelines. The bill is in early legislative stages (referred to House Energy and Commerce) with no funding attached, limiting near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9661 would reduce clinical trial requirements for biosimilar approval, lowering development costs by an estimated 20-40%
- 2.The bill is early stage (referred to committee) with no funding, so market impact is limited until passage
- 3.Biosimilar developers $VTRS and $TEVA are primary beneficiaries of the regulatory change
Market Implications
The bill, if enacted, would structurally benefit biosimilar manufacturers by reducing the cost and time of FDA approval. This could accelerate biosimilar market share gains against originator biologics, improving margins for $VTRS and $TEVA. However, the legislative process is at its earliest stage, so no immediate price movement is expected. Investors should watch for committee hearings and markups as indicators of momentum.
Full Analysis
On July 14, 2026, Rep. Langworthy (R-NY) introduced HR9661 in the 119th Congress. The bill amends the Public Health Service Act to specify that, as a default, the FDA should not require clinical studies assessing pharmacodynamics or comparative clinical efficacy when evaluating a biosimilar biological product for licensure. This would codify a more streamlined approval pathway, reducing the evidence burden on biosimilar applicants. The bill has one original cosponsor, Rep. Schrier (D-WA), giving it bipartisan support but no senior committee leadership sponsorship. It was referred to the House Committee on Energy and Commerce, where it awaits further action. There is no funding amount in the bill; it is a regulatory change only. The money trail is indirect: lower clinical trial costs translate to higher margins and faster market entry for biosimilar developers. There is no convergence with the provided presidential action (chemical manufacturing regulatory relief), which is unrelated. Structural winners are biosimilar-focused companies: $VTRS (Viatris) and $TEVA (Teva), whose biosimilar portfolios benefit from reduced development expenses. Originator biologic companies ($JNJ, $LLY, $REGN) face increased competition, but the bill is early stage, so the effect is not immediate. The timeline: The bill must pass committee markup, then the full House, then the Senate, then be signed by the President. As an early-stage referral, near-term passage probability is low, but the bipartisan sponsorship may accelerate committee consideration.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Regulatory change reducing the default requirement for clinical studies (pharmacodynamics and comparative clinical efficacy) in biosimilar licensure applications
Who must act
FDA Center for Drug Evaluation and Research (CDER) – Office of Therapeutic Biologics and Biosimilars
What happens
Lower clinical trial costs and accelerated FDA review timelines for biosimilar applications, reducing per-application development costs by an estimated 20-40%
Stock impact
Viatris' biosimilar pipeline (e.g., Semglee, Hulio, and future candidates) benefits from reduced R&D expenses, improving margin profile and enabling faster market entry against originator biologics
What the bill does
Same regulatory change – codification that FDA's default expectation for biosimilar approval does not require clinical pharmacodynamics or comparative efficacy studies
Who must act
FDA CDER
What happens
Reduced development costs and shorter time-to-market for biosimilar applications, increasing the number of affordable biosimilar entrants
Stock impact
Teva's biosimilar portfolio (e.g., Truxima, Herzuma, and pipeline) sees lower development costs, improving profitability and competitive positioning against originator biologics
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Ensuring Access to Lower-Cost Medicines for Seniors Act
Expedited Access to Biosimilars Act
CLEAR LABELS Act
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $1.5B Department of Homeland Security Grant
GEORGIA EMERGENCY MANAGEMENT AND HOMELAND SECURITY AGENCY: $1.6B Department of Homeland Security Grant
GOVERNOR'S AUTHORIZED REPRESENTATIVE: $1.8B Department of Homeland Security Grant
NORTH CAROLINA DEPARTMENT OF PUBLIC SAFETY: $2.4B Department of Homeland Security Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →